Oregon Gov. Kate Brown said the DEA’s ruling “makes it more hard for states that have legalized marijuana use, or who are poised to, to proceed lawfully and safely”.
Advertisement
“This change illustrates DEA’s commitment to working together with the FDA and NIDA [National Institute on Drug Abuse] to facilitate research concerning marijuana and its components”, the agency said in a statement. “Rosenberg gave “enormous weight” to conclusions by the Food and Drug Administration that marijuana has “no now accepted medical use in treatment in the United States”, and by some measures, it remains highly vulnerable to abuse as the most commonly used illicit drug across the nation”. The list includes heroin, LSD, ecstasy and marijuana. Ultimately, the DEA’s decision is a neutral to the marijuana industry.
Loosening that definition could encourage scientific study of a drug that is being used to treat diseases in several USA states despite little proof of its effectiveness.
“Marijuana lacks accepted safety for use under medical supervision”.
Kampia said he’s spent more than 20 years fighting for states to determine their own marijuana policies without federal interference. “Therefore, HHS recommended that marijuana remain in Schedule I”. The agency said it will allow more groups to register to grow and distribute marijuana for the purposes of FDA-authorized research.
Drugs listed on the DEA’s Schedule I list meet three criteria – a high potential for abuse, no now accepted medical use and a lack of accepted safety for the drug’s use under medical supervision.
The Drug Enforcement Administration has promised Thursday that it will make certain changes to easy things for research and private companies to grow and have access to marijuana for research purposes. However, marijuana use is still considered an offense under Federal law.
The DEA rejected requests Thursday to remove marijuana from its Schedule I list of controlled substances, saying it has “no now accepted medical use”.
In the words of a 2015 Brookings Institution report, a move to Schedule II “would signal to the medical community that [the Food and Drug Administration] and [the National Institutes of Health] are ready to take medical marijuana research seriously, and help overcome a government-sponsored chilling effect on research that manifests in direct and indirect ways”.
He said the DEA’s decision also doesn’t address concerns surrounding banking or tax deductions.
Advertisement
Marijuana is legal in some form or another in 23 states plus Washington, DC.
